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Abstract
Background: We sought to identify candidate serum biomarkers for the detection and surveillance of EOC. Based
on RNA-Seq transcriptome analysis of patient-derived tumors, highly expressed secreted proteins were identified
using a bioinformatic approach.
Methods: RNA-Seq was used to quantify papillary serous ovarian cancer transcriptomes. Paired end sequencing of
22 flash frozen tumors was performed. Sequence alignments were processed with the program ELAND, expression
levels with ERANGE and then bioinformatically screened for secreted protein signatures. Serum samples from
women with benign and malignant pelvic masses and serial samples from women during chemotherapy regimens
were measured for IGFBP-4 by ELISA. Student’s t Test, ANOVA, and ROC curves were used for statistical analysis.
Results: Insulin-like growth factor binding protein (IGFBP-4) was consistently present in the top 7.5% of all
expressed genes in all tumor samples. We then screened serum samples to determine if increased tumor
expression correlated with serum expression. In an initial discovery set of 21 samples, IGFBP-4 levels were found to
be elevated in patients, including those with early stage disease and normal CA125 levels. In a larger and
independent validation set (82 controls, 78 cases), IGFBP-4 levels were significantly increased (p < 5 × 10
-5). IGFBP-4
levels were ~3× greater in women with malignant pelvic masses compared to women with benign masses. ROC
sensitivity was 73% at 93% specificity (AUC 0.816). In women receiving chemotherapy, average IGFBP-4 levels were
below the ROC-determined threshold and lower in NED patients compared to AWD patients.
Conclusions: This study, the first to our knowledge to use RNA-Seq for biomarker discovery, identified IGFBP-4 as
overexpressed in ovarian cancer patients. Beyond this, these studies identified two additional intriguing findings.
First, IGFBP-4 can be elevated in early stage disease without elevated CA125. Second, IGFBP-4 levels are
significantly elevated with malignant versus benign disease. These findings provide the rationale for future
validation studies.
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Background
Epithelial Ovarian Cancer (EOC) is the most lethal
female reproductive tract malignancy with nearly
200,000 new cases and > 125,000 deaths attributable to
the disease each year worldwide [1]. The high fatality-
to-case ratio is due, in part, to lack of effective screening
modalities to detect ovarian cancer at an early stage
wherein rates of cure exceed 90%. Most patients present
with advanced stage disease and the cornerstone of
treatment is surgical debulking followed by platinum-
based chemotherapy. The other major contributor to
the high fatality-to-case ratio is chemoresistant disease.
In fact, while 80% of patients have a complete clinical
response to their primary therapy, the majority will die
from disease recurrence within 5 years. The overall
worldwide 5-year survival rate of the disease is < 40%
[2], however, when detected early, the 5-year survival
rate more than doubles [3]. Unfortunately, EOC has
non-specific, vague, gastrointestinal, and often ignored
symptoms such as bloating, irregularity, and indigestion
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ods, making early detection difficult and uncommon.
The search for reliable, specific, and sensitive serum-
based biomarkers for EOC has a long history and its
major highlight remains the identification of CA125
nearly 30 years ago [4]. Although CA125 is expressed in
a majority (~80%) of late stage disease, it is elevated in
only a subset (~50%) of early disease, thus limiting its
usefulness for early disease detection [5]. In an attempt
to overcome this limitation, proteomic-based studies
have sought novel biomarkers. Examples of promising
markers found through candidate and proteomic
approaches include HE4, transthyretin, and CA72.4
[6-8]. Nonetheless, no markers are approved for popula-
tion screening or disease detection whereas only CA125,
along with HE4, are approved for monitoring of recur-
rent disease [9]. The history of poor performance of
individual markers has led researchers to also evaluate
panels or combination markers [6,7,10,11].
Next Generation Sequencing technologies, as applied
to cancer genomes and transcriptomes, has allowed a
relatively unbiased and more complete view of the glo-
bal changes that define tumors [12,12-14]. Specifically,
analyses of melanoma, pancreatic, lung, and breast can-
cers have revealed key pathways and genes affected in
these cancers by mutations, copy number variations,
and transcriptional changes [12,12-14]. Furthermore,
application of this knowledge can be used to discover
both personalized and global diagnostic and prognostic
biomarkers [3,15]. We hypothesized that application of
RNA-Seq technology to ovarian cancer could identify
overexpression of secreted proteins that could act as
novel biomarkers.
We analyzed the global gene expression patterns of a
highly clinically annotated sample set of EOC represent-
ing both early and late stage tumors by RNA-Seq.
Focusing specifically on transcripts that had evidence for
secretion of their translated protein products, we identi-
fied IGFBP-4 to be highly expressed across all stages of
EOC. IGFBP-4 is one of six IGFBP’s, a family of regula-
tors of normal and tumor cell biology [16], whose func-
tion is to inhibit IGF-I and -II binding to their
receptors, IGF1R and IGF2R [17]. It is present in all
body-fluids, secreted primarily by the liver, but also
expressed by a number of organs, including the ovaries.
In the ovary, it is involved in follicle selection and is
upregulated in vivo and in vitro in response to estrogen
[17]. Tumor expression of IGF family members has
been linked to breast, endometrial, colon, and skin can-
cers [16]. In this study, we demonstrate that IGFBP-4
serum levels were significantly upregulated in primary
and recurrent EOC patients even in a number of cases
where CA125 levels were within normal limits.
Methods
Patients and Specimen Collection
EOC tumor samples were collected from Mount Sinai
School of Medicine (New York, USA) and San Gerardo
Hospital (Milan, Italy) patients at the time of surgery
under their respective IRB-approved protocols. Samples
were divided in the operating room and a portion sent
for pathology confirmation and staging. Portions were
flash frozen for RNA and protein analysis or used
immediately for generating patient-derived cell lines.
Papillary serous tumor samples were collected across all
stages (five stage I/II, 11 stage III/IV, two disseminated
peritoneal lesions, and two recurrent tumors). For com-
parison, two borderline tumors were also sequenced.
Blood samples were collected in gold top tubes (BD
Biosciences, Franklin Lakes, New Jersey) directly prior
to surgery, directly prior to chemotherapy, or at clinical
office visits (controls), allowed to clot and centrifuged at
2600 rpm for 10 minutes to separate serum. Serum
samples were aliquoted to minimize freeze thaw cycles
and stored at -130°C. Patient characteristics including
age, ethnicity, stage/grade of tumor are provided in
Additional File 1: Table S1. Control samples were col-
lected at the time of routine office visits.
For disease surveillance studies, blood samples were
serially collected during each chemotherapy infusion,
and in subsequent office visits thereafter. IGFBP-4 levels
were measured for each visit, or averaged over the entire
postsurgical period to give a composite value. Additional
File 2: Table S2 highlights patient characteristics and
treatment regimens. Disease recurrence status was
assessed by a combination of positive CT/PET scans,
CA125 levels, and/or positive operative laparoscopy.
RNA extraction
RNA was extracted from frozen tissue using QIAzol
according to the manufacturer’s instructions (Qiagen,
Valencia, California). Briefly, tissue was homogenized in
QIAzol on ice. Chloroform was added, mixed and cen-
trifuged to allow for separation and removal of the aqu-
eous layer. RNA was precipitated in isopropanol
overnight at -20°C. The suspension was centrifuged to
pellet the RNA, washed with 75% ethanol and then
resuspended in RNAase-free water. RNA integrity num-
bers (RINs) were determined (Agilent Bioanalyzer, Agi-
lent Technologies, Santa Clara, California) and only
RNA with a RIN score of ≥ 8.0 was submitted for next-
generation sequencing.
RNA-Seq
Epithelial ovarian cancer transcriptomes were prepared
for paired-end sequencing using the Illumina GAII plat-
form by the manufacturer’s protocols and with a second
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were aligned using the software program ELAND32
(provided with the Illumina sequencing platform).
Expression levels were quantified by running ERANGE
v. 3.0.2. [18]. For each gene, ERANGE reported the
number of mapped reads per kilobase of exon per mil-
lion mapped reads (RPKM).
Quantitative Real-time Reverse Transcription PCR (qRT-
PCR)
RNA-Seq data was confirmed by qRT-PCR. One micro-
gram of RNA was reverse transcribed using the BioRad
Iscript system (BioRad, Hercules, California). qRT-PCR
was performed on an ABI PRISM 7900HT sequence
detection system (Applied Biosystems, Carlsbad, Califor-
nia). Cycle number values were normalized against two
housekeeping genes, B2M and GAPDH. Data shown are
the averages of three separate experiments, each per-
formed in triplicate. The IGFBP-4 primers used were
IGFBP-4 Fwd: 5’- AGGTCCTTCCTTTAGGTCTG-3’ and
IGFBP-4 Rev: 5’- GGAAGACTTGAAGCACAGAG-3’.
ELISA
Patient serum IGFBP-4 levels were analyzed in duplicate
using Active IGFBP-4 ELISA (Diagnostic Systems
Laboratories, Inc, a Beckman Coulter Company, Web-
ster, Texas) according to the manufacturer’sp r o t o c o l .
Standards and internal controls were assayed on each
plate for calibration and consistency. Colorimetric
absorbance was detected using a microplate reader at
450 nm with a background correction at 620 nm. A
standard curve was generated for each plate and sample
IGFBP-4 concentrations determined.
Statistical Analysis
Statistical differences were determined using the Stu-
dent’s t test or ANOVA with Bonferroni correction and
post-hoc test. ROC analysis was performed using SPSS
software (IBM, Chicago, Illinois).
Results
IGFBP-4 is expressed in early, late, and recurrent EOC
tumors
Paired-end sequencing reads were aligned to the gen-
o m ea n dt h en u m b e ro fr e a d sm a p p i n gt oas p e c i f i c
mRNA transcript expressed as coverage. Coverage
adjusts the number of mapped reads by the overall
length of the mRNA transcript as longer transcripts will
necessarily have more mapped reads than a shorter
transcript expressed at the same level. Approximately
10,000 transcripts were expressed at an average coverage
level greater than one in the 22 tumor samples
sequenced. This list was then cross-referenced against
the Secreted Protein Database [19] to identify tumor-
expressed genes that could be secreted into the serum
and therefore useful as potential biomarkers. This analy-
sis yielded a working dataset of ~1700 transcripts. It was
necessary for the potential biomarker to be expressed by
a majority of tumors and we therefore looked for candi-
dates with minimal variation among samples. For this
reason, transcripts with a standard deviation greater
than 75% of the average expression level were disquali-
fied from further analysis (68%, 1169 transcripts). The
remaining 541 transcripts (32%) were designated “top
candidate genes”. And from this list, we selected IGFBP-
4a sa“proof-of-principle” candidate based on pathway
analysis, proposed upregulation in other cancers as well
as the availability of a commercial antibody. Importantly,
we found no previous reports examining serum IGFBP-4
in ovarian cancer in the literature.
IGFBP-4 ranked among the top 7.5% (average top 3%)
of expressed genes across all tumor samples. The aver-
age coverage levels between the different tumor types
are shown in Table 1. For a comparison and validation
of our system, we examined the expression level of a
number of previously described ovarian cancer markers.
CA125 averaged in the top 8% (average coverage level
18.426). Interestingly, HE4 was highly expressed; it was
on average in the top 10 genes expressed with an aver-
age coverage level of 435.8. Putative markers CA72.4
and transthyretin were not present in our top 10% gene
list.
From the same tumor RNA samples that were
sequenced, cDNA was synthesized and RT-PCR used to
validate expression profiles (Additional File 3: Table S3).
To confirm our RNA-Seq findings, we analyzed an inde-
pendent validation set of an additional 22 tumor sam-
ples by qRT- PCR. IGFBP-4 was again highly expressed
in all samples (data not shown).
Serum IGFBP-4 is elevated in EOC patients even those
with normal CA-125
To quantify IGFBP-4 serum protein expression levels in
patients compared to controls, ELISA assays were used.
We first chose a subset of “discovery” samples to
Table 1 RNA-Seq tumor coverage values
Disease Group Mean (StDev) Range N#
Borderline 55.035 (14.425) 44.835-65.235 2
Early EOC 18.796 (16.450)*♮ 4.280-37.895 5
Late EOC 18.745 (14.412)*♮ 6.335-60.005 11
Disseminated 13.893 (10.737)*♮ 6.300-21.485 2
Recurrent 54.923 (17.999) 42.195-67.650 2
Coverage units is transcripts, adjusted to the full length of the mRNA
transcript of IGFBP-4.
Statistical significance was tested using a Student T-test. *statistically different
from borderline;
♮ statistically different from recurrent tumors
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found the 21 patient samples (five stage I, one stage II,
six stage III, one stage IV, and eight recurrent EOC) to
have significantly higher levels of IGFBP-4 compared to
controls (Figure 1, p < 0.0001). All of the primary sam-
ples and all but 2 of the 8 recurrent EOC samples had
levels greater than that of the controls. Although the
sample size for these data was limited, they provide the
rationale for future studies including larger numbers of
patients.
Given that CA125 is historically non-informative in
~20% of women with ovarian cancer at the time of their
initial diagnosis, we also sought to compare the sensitiv-
ity of IGFBP-4 to that of CA125 [20]. Of interest, while
eight of the 21 cases had CA125 levels within normal
limits, seven of these had elevated IGFBP-4 levels (Fig-
ure 1, cases highlighted with an asterisk). Conversely, of
the two recurrent patients with low IGFBP-4, only one
had elevated CA125 while the other had a CA125 below
threshold (Figure 1).
Based on these results, we then analyzed a larger vali-
dation cohort consisting of 82 healthy controls and 78
cases. Cases consisted of 6 patients with benign ovarian
disease, 16 early EOC (stage I/II) cases, 40 late EOC
(stage III/IV) cases, and 16 recurrent cases (Additional
File 1: Table S1). EOC cases again had significantly
higher levels of IGFBP-4 than healthy and benign con-
trols (*p < 0.05, **p < 5 × 10
-7, ***p < 5 × 10
-11 Figure
2A, B). EOC (all stages) had an average IGFBP-4 of
1344.09 ng/ml compared to 400.9 ng/ml for healthy
controls and 394.6 ng/ml for benign controls (Table 2).
To analyze the sensitivity and specificity of IGFBP-4 as
a marker for EOC we next performed ROC (Receiver
Operating Characteristics) analysis. An ROC curve
defining controls as both healthy and benign patients
and cases as all EOC (early, late, and recurrent) had an
area under the curve (AUC) of 0.700 (Figure 2C, p <
0.0005). Setting the specificity at 90%, sensitivity was
45.3%, with a threshold value of 1064.5 ng/ml. When
the specificity was increased to 95%, sensitivity became
36.8% and the threshold was set at 1304.7 ng/ml.
Given the interest and clinical relevancy in differen-
tiating between benign and malignant adnexal masses
p r i o rt os u r g e r y ,w ea l s oc o m p a r e db e n i g nv e r s u sc a n -
cer. When we used the benign cases alone as the control
group, sensitivity increased at the high specificities
required for high positive predictive values (Figure 2D).
The ROC curve had an AUC of 0.816 and the threshold
Figure 1 IGFBP-4 is upregulated in patient serum samples compared to controls. Patient and control serum samples were analyzed by
ELISA and IGFBP-4 concentrations determined and graphed (pink bars). Samples with IGFBP-4 levels less than control values are light pink and
IGFBP-4 levels greater than controls are dark pink. As a comparison, CA125 levels for patients are graphed in green. Using the standard cutoff of
35 U/ml, CA125 levels were divided into high (dark green) and low (light green). Those patients where IGFBP-4 was a better marker (low CA125
but high IGFBP-4) are indicated with an asterisk.
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sitivity of 73%.
IGFBP-4 as a disease surveillance biomarker
To analyze the potential of IGFBP-4 to monitor for dis-
ease recurrence and chemotherapeutic response, we col-
lected serum samples from 10 patients undergoing
chemotherapy following their surgical tumor removal
(one stage I, one stage II, five stage III, two stage IV, and
one recurrent). Patient characteristics are provided in
Additional File 2: Table S2. Serum levels were tested dur-
ing chemotherapeutic regimens in order to monitor the
correlation between tumor status and IGFBP-4 levels.
Our hypothesis was that IGFBP-4 levels may provide
insight into tumor behaviour, ie resistance or recurrence.
Follow-up after final serum collection was between 7 and
16 months. Patients were triaged into two groups, no evi-
dence of disease (NED, n = 5) or alive with disease
(AWD, n = 5). Follow-up period did not vary significantly
between groups (Table 3, 13.2 months in AWD, 11.8
months in NED, p = 0.592) although the NED group was
significantly younger (Table 3, NED average age 48 years,
AWD average age 58.8 years, p < 0.005) and represented
earlier stage disease than the AWD group (Table 3, aver-
age stage 3.2 in AWD, 2.6 in NED, p = 0.305)
The average IGFBP-4 levels of each patient following
surgery trended lower in the NED compared to the
AWD group (p < 0.10). Most interestingly, 58% (19/33)
of the IGFBP-4 AWD measurements were above the
1000 ng/ml threshold (determined in ROC analysis
above) compared to only 23% (8/35) in the NED group.
The average IGFBP-4 reading for the NED group was
significantly less than the AWD group (NED = 854.49,
AWD = 1206.53 ng/ml, p < 0.005, Figure 3).
Figure 2 Serum IGFBP-4 level analysis. (A, B) Box and whisker graphs shows average (central line), quartile levels (top and bottom of box),
minimum and maximum (ends of whiskers) IGFBP-4 levels in each group. (A) All controls (healthy and benign) compared to all stages of EOC
(***p < 5 × 10
-7). (B) Early, late and recurrent EOC groups have significantly higher IGFBP-4 levels than control or benign groups (*p < 0.05, **p
< 0.005). See Table 2 for average values and ranges. Serum IGFBP-4 level ROC analysis of (C) all controls (healthy and benign samples) and all
EOC cases (early, late, and recurrent) results in an AUC of 0.700. (D) ROC curve comparing benign controls only to all cases resulted in an AUC of
0.816. Corresponding sensitivity, specificity, and threshold values are listed below each curve.
Table 2 Serum IGFBP-4 levels
Disease Group Mean (StDev) Range N#
Control 400.95 (470.8) 13.5-1602.8 82
Benign 394.60 (226.8) 83.2-744.9 6
Early EOC 1334.50 (1117.7)*♮ 20.9-3323.3 16
Late EOC 1305.40 (889.3)*♮ 41.4-3360.1 40
Recurrent 1450.4 (1039.3)*♮ 65.3-3583.2 16
Units are μg/ml. Statistical significance was tested using a Student T-test.
*Statistically different from control; ♮ statistically different from benign
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Using whole transcriptome analysis across all stages of
EOC, we initially identified IGFBP-4 as a secreted pro-
tein highly expressed in all tumors. We then confirmed
and quantitated IGFBP-4 overexpression in patient
serum samples. To our knowledge, this is the first
report demonstrating increased serum IGFPB-4 expres-
sion in ovarian cancer patients.
Despite large and significant differences between mean
IGFBP-4 levels in cases and controls, ROC analysis
revealed limited sensitivity at the specificities required
for a simple single marker ovarian cancer screening test
(Figure 2C, D). This is due to the level of overlap
between the controls and cases which makes differen-
tiating the two groups more complex. Above all, the low
occurrence rate of EOC, combined with invasive nature
of first-line treatment (surgical cytoreduction combined
with chemotherapy), require a very high specificity, sug-
gested to be at least 99.6% and a sensitivity of at least
75% to yield a positive predictive value of 10 [21]. None-
theless, our studies suggest that, with further study,
determination of IGFBP-4 levels could provide use in
three clinical settings.
First, as shown in Figure 1, IGFBP-4 serum levels can
be significantly increased in cases of early- and late-
stage disease even when CA125 is within normal limits.
Notably, three of the six early-stage cases with normal
CA125 levels had increased IGFBP-4 levels. Therefore,
combining IGFBP-4 and CA125 could increase the sen-
sitivity for detecting EOC, especially, early stage disease.
Future studies will be required.
Second, it has now been recommended that women
with a suspicious adnexal mass should be referred to a
gynecologic oncologist for evaluation since the early dis-
tinction between a benign and malignant mass repre-
sents an important clinical decision point. [reviewed in
[22]].. In our patient cohort, malignant masses were
associated with average IGFBP-4 levels ~3× higher than
benign masses (Figure 2). When assay specificity is set
at 94%-the highest we could achieve, given the number
of samples in our dataset -, sensitivity is 73%. Increasing
t h es a m p l es i z e sf o rt h e s es t u d i e sw i l li n c r e a s et h e
power of the analysis and will allow us to better analyze
the overlap between and variability within groups. It will
therefore be of future interest to increase sample sizes
and re-evaluate the clinical utility of IGFBP-4 alone or
in combination with other markers for distinguishing
between benign and malignant masses.
Finally, we investigated the potential use of IGFBP-4
as a biomarker to monitor disease recurrence and resis-
tance to treatment in patients receiving chemotherapy.
While levels did not reach statistical significance, there
was a trend for NED patients to have lower average
IGFPB4 levels compared to AWD patients. Although
levels in chemotherapy patients did not always remain
below the ROC-determined threshold of 1000 ng/ml,
those whose cumulative IGFBP-4 level average was less
Table 3 Follow-up patient characteristics
Group Age (Range)* Stage Follow-up
AWD 58.8 (55-65) 3.2 13.2
NED 48 (44-55) 2.6 11.8
aAverage stage found by assigning values to each stage as follows: Stage I =
1, II = 2, III = 3, IV = 4, Recurrent = 5; *p < 0.005
Figure 3 Serum IGFBP-4 levels increased in EOC post-operative patients with recurrent or persistent disease. A) Cumulative average
IGFBP-4 serum levels for patients assessed as either NED or AWD. Average value for each group is shown as horizontal green (NED) or red
(AWD) lines, p = 0.178. B) Serial serum IGFBP-4 measurements for NED or AWD patients. Average value for each group is shown as horizontal
green (NED) or red (AWD) lines, ***p < 0.005.
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group than those with higher averages (Figure 3). More-
over, the percentage of serial IGFBP-4 readings above
threshold was higher in the AWD group compared to
the NED group, again suggesting that high serum levels
of IGFBP-4 may be indicative of disease state. Although
differences in age and stages between the two groups
(Additional File 2: Table S2) may contribute to this dif-
ference, we believe it unlikely given that in our larger
diagnostic data set there was no difference between
early EOC IGFBP-4 levels and later stage disease levels
(early average 1334.5 ng/ml, late average 1305.4 ng/ml,
p = 0.91, Figure 2). Additionally, we did not find any
correlation between age and IGFBP-4 levels in either
cases or controls (Additional File 4: Figure S1, R
2 =
0.003), although a positive correlation has been pre-
viously reported in healthy individuals [23]. Finally, it
should be noted that the chemotherapy regimens
received by women with disease recurrence were not
always uniform between the groups. In such a small
sample set, and in such a novel study, it is unknown at
this time what effect, if any, these differences in agents
may have had on IGFBP-4 levels.
Future studies are planned primarily to increase
sample size and diversity of patients. Unexpectedly,
we noted that Hispanic cases have significantly higher
serum IGFPB-4 levels compared to other non-Hispa-
nic cases or all controls (Additional File 5: Table S4).
We are unaware of previous reports or studies sug-
gesting a biologic basis for this finding. Thus, this
intriguing finding will be specifically explored in
future studies.
The IGF pathway has been implicated in carcinogen-
esis [16] and the role of IGFBP-4 has been studied in a
number of human malignancies, including lung, endo-
crine (thyroid and adrenal), breast, prostate, and hepato-
cellular cancers [17]. Increased serum IGFBP-4 levels
have also been associated with breast cancer, melanoma,
and acute lymphoblastic leukemia [17,24]. While no pre-
vious reports have examined IGFBP-4 serum levels in
ovarian cancer patients, IGFBP-4 was one of 52 proteins
identified in a proteomic analysis of EOC ascites fluid
although serum levels were neither evaluated nor com-
pared with control samples [25]. At this time it is
unclear how increased levels of IGFBP-4 may relate to
initiation or progression of ovarian cancer. Our findings
may initially seem counterintuitive, as the understood
role of IGFBP-4 is to bind to and inhibit IGF-I and IGF-
II, thereby suppressing cell growth and proliferation. In
cancer settings, however, it is suggested to do exactly
the opposite [17,24]. One possible explanation pertains
to the hormone responsiveness of IGFBP-4. In an estro-
gen-rich environment that may occur as a result of
ovarian cancer, IGFBP-4 is thereby over stimulated, and
could serve as a marker for this subset of cancers. In a
second scenario, involving the known role of IGFBP-4
in follicle stimulation, IGFBP-4 becomes constitutively
expressed over years of repeated ovulation, and this con-
tinued expression might drive overgrowth of the epithe-
lial cell layer of the ovary, contributing directly to the
growth of the tumor. At best, these hypotheses are spec-
ulative, and biologic proof is required. However, given
the suggestion of diagnostic and prognostic significance,
as well as the potential as a therapeutic or preventative
target, we believe these future studies worthwhile. These
studies may work specifically to address issues of sam-
ples size, adjust for patient ethnicity and investigate the
molecular role of IGFBP-4 is carcinogenesis of
progression.
Conclusion
In sum, our studies have identified that serum IGFBP-4
is on average upregulated ~3-fold in EOC cases com-
pared to either healthy population controls or in those
women with benign ovarian masses. This upregulation
is present across all stages of EOC, including early stage
disease and in women with recurrence of their cancer
following treatment. Finally, IGFBP-4 levels can be ele-
vated in women with early stage disease, whose CA125
levels are within normal limits. Based on these findings,
we believe IGFBP-4 represents an interesting candidate
biomarker for detection and surveillance of papillary ser-
ous ovarian cancer.
Additional material
Additional file 1: Table S1. Supplementary Table 1: Patient and tumor
demographics.
Additional file 2: Table S2. Supplementary Table 2: Patient
demographic and chemotherapeutic data.
Additional file 3: Table S3. Supplementary Table 3: qRT-PCR tumor
coverage values.
Additional file 4: Figure S1. Serum IGFBP-4 levels are not significantly
correlated with age. Scatter plot of serum IGFBP-4 levels against age of
both cases and controls shows no correlation between to the two.
Additional file 5: Table S4. Supplementary Table 4: IGFBP-4 and age by
ethnicity.
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